The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
Abstract
The current phase of drug development is witnessing an oncoming crisis due to the combined effects of increasing R&D costs, decreasing number of new drug molecules being launched, several blockbuster drugs falling off the patent cliff, and a high proportion of advanced drug candidates exhibiting poor aqueous solubility. The traditional approach of salt formulation to improve drug solubility is unsuccessful with molecules that lack ionizable functional groups, have sensitive moieties that are prone to decomposition/racemization, and/or are not sufficiently acidic/basic to enable salt formation. Several novel examples of pharmaceutical cocrystals from the past decade are reviewed, and the enhanced solubility profiles of cocrystals are analyzed. The peak dissolution for pharmaceutical cocrystals occurs in a short time (<30 min), and high solubility is maintained over a sufficiently long period (4–6 h) for the best cases. The enhanced solubility of drug cocrystals is similar to the supersaturation phenomenon characteristic of amorphous drugs. However, in contrast to the metastable nature of amorphous phases, cocrystals are stable owing to their crystalline nature. Yet, cocrystals can exhibit dramatic solubility advantage over the stable crystalline drug form, often comparable to amorphous pharmaceuticals. The “spring and parachute” concept for amorphous drug dissolution is adapted to explain the solubility advantage of pharmaceutical cocrystals. Thus (1) the cocrystal dissociates to amorphous or nanocrystalline drug clusters (the spring), which (2) transform via fast dissolving metastable polymorphs to the insoluble crystalline modification following the Ostwald’s Law of Stages, to give (3) high apparent solubility for cocrystals and optimal drug concentration (the parachute) in the aqueous medium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis
Desiraju, G. R. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199523111 · Cited by 4,856
Encoding and decoding hydrogen-bond patterns of organic compounds
Etter, M. C. (1990) · Accounts of Chemical Research · doi:10.1021/ar00172a005 · Cited by 4,591
Studien über die Bildung und Umwandlung fester Körper: 1. Abhandlung: Übersättigung und Überkaltung
Ostwald, W. (1897) · Zeitschrift für Physikalische Chemie · doi:10.1515/zpch-1897-2233 · Cited by 2,103
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates
Blagden, N., de Matas, M., Gavan, P. T., & York, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.011 · Cited by 1,448
Salt formation to improve drug solubility
Serajuddin, A. T. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.010 · Cited by 1,425
Amorphous pharmaceutical solids: preparation, characterization and stabilization
Yu, L. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00098-9 · Cited by 1,405
What is the True Solubility Advantage for Amorphous Pharmaceuticals?
Hancock, B. C., & Parks, M. (2000) · Pharmaceutical Research · doi:10.1023/a:1007516718048 · Cited by 1,358
Solubility Advantage of Pharmaceutical Cocrystals
Good, D. J., & Rodríguez-Hornedo, N. (2009) · Crystal Growth & Design · doi:10.1021/cg801039j · Cited by 841
Cited by
Crystal Engineering: From Molecule to Crystal
Desiraju, G. R. (2013) · Journal of the American Chemical Society · doi:10.1021/ja403264c · Cited by 1,517
Baghel, S., Cathcart, H., & O'Reilly, N. J. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.10.008 · Cited by 970
Pharmaceutical cocrystals and poorly soluble drugs
Thakuria, R., Delori, A., Jones, W., Lipert, M. P., Roy, L., & Rodríguez-Hornedo, N. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.043 · Cited by 614
Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs
Bolla, G., Sarma, B., & Nangia, A. K. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00987 · Cited by 597
Self-citationPharmaceutical amorphous solid dispersion: A review of manufacturing strategies
Bhujbal, S. V., Mitra, B., Jain, U., Gong, Y., Agrawal, A., Karki, S., Taylor, L. S., Kumar, S., & (Tony) Zhou, Q. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.014 · Cited by 556
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs
Censi, R., & Di Martino, P. (2015) · Molecules · doi:10.3390/molecules201018759 · Cited by 512
Berry, D. J., & Steed, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.003 · Cited by 406
Zhou, B., & Yan, D. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201807599 · Cited by 387
Pharmaceutical cocrystals: from serendipity to design to application
Kavanagh, O. N., Croker, D. M., Walker, G. M., & Zaworotko, M. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.023 · Cited by 323
Eutectics as improved pharmaceutical materials: design, properties and characterization
Cherukuvada, S., & Nangia, A. (2014) · Chem. Commun. · doi:10.1039/c3cc47521b · Cited by 296
Self-citationFast Dissolving Curcumin Cocrystals
Sanphui, P., Goud, N. R., Khandavilli, U. B. R., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200704s · Cited by 253
Self-citationThe Integration of Artificial Intelligence into Clinical Practice
Karalis, V. D. (2024) · Applied Biosciences · doi:10.3390/applbiosci3010002 · Cited by 255
Nanocrystals: a perspective on translational research and clinical studies
Jarvis, M., Krishnan, V., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10122 · Cited by 162
Metadata
- Authors
- Babu, N. J., & Nangia, A.
- Venue
- Crystal Growth & Design
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-06-02
- Volume
- 11
- Issue
- 7
- Pages
- 2662-2679
- ISSN
- 1528-7483 (ISSN-L)
- 1528-7505
- OpenAlex
- W2335434301
- Cited by
- 1,004
- References
- 47
- FWCI
- 21.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.